Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma
- 30 April 1996
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (4) , 730-733
- https://doi.org/10.1016/0959-8049(95)00662-1
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.Journal of Clinical Oncology, 1993
- Biochemotherapy using interleukin-2 + interferon alpha-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanomaMelanoma Research, 1993
- SUBCUTANEOUS RIL-2 IN ADVANCED MELANOMA AND KIDNEY CARCINOMAInternational Journal of Oncology, 1992
- Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.Journal of Clinical Oncology, 1992
- Effective chemotherapy for melanoma after treatment with interleukin-2Cancer, 1992
- Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.Journal of Clinical Oncology, 1991
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaCancer, 1990
- In Vitro and In Vivo Effects of Cisplatin on the Generation of Lymphokine-Activated Killer CellsJNCI Journal of the National Cancer Institute, 1990
- Reporting results of cancer treatmentCancer, 1981